EP300 and Hyperglycemia: Therefore, p300 has been proposed to be a prime factor leading to the development of hyperglycemia, impaired insulin levels and insulin resistance (Cao et al., 2017; Yao et al., 2018), which frequently occur in individuals treated with second-generation APs (Newcomer et al., 2002; Henderson et al., 2005; Teff et al., 2013).